Bristol-Myers Squibb ROA 2006-2018 | BMY

Current and historical return on assets (ROA) values for Bristol-Myers Squibb (BMY) over the last 10 years.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $94.122B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $337.858B 16.72
Pfizer (PFE) United States $223.411B 13.75
Novartis AG (NVS) Switzerland $182.569B 15.82
Merck (MRK) United States $169.563B 15.15
AbbVie (ABBV) United States $153.340B 15.64
Novo Nordisk (NVO) Denmark $121.883B 20.19
Sanofi (SNY) France $105.164B 13.31
GlaxoSmithKline (GSK) United Kingdom $103.492B 14.15
Eli Lilly (LLY) United States $97.374B 19.33
AstraZeneca (AZN) United Kingdom $94.122B 9.86